Advances in Antibody–Drug Conjugates for Treatment of Non-Small-Cell Lung Cancer

Get up to date on integrating emerging antibody–drug conjugates into the care of your patients with non-small-cell lung cancer with an interactive on-demand Webcast and downloadable slides with ExpressPoints slides from the virtual symposium.
D. Ross Camidge, MD, PhD
Joel W. Neal, MD, PhD

ClinicalThought

In this commentary, D. Ross Camidge, MD, PhD, provides his thoughts on the latest advances and potential of ADCs in the treatment of non-small-cell lung cancer.

D. Ross Camidge, MD, PhD Released: January 26, 2021

Downloadable Slidesets

Download this slideset to gain expert insight into the current status of investigational antibody-drug conjugates for NSCLC.

D. Ross Camidge, MD, PhD Released: February 9, 2021

Download this slideset to gain expert insight into the activity of antibody-drug conjugates within the clinical trial setting for NSCLC.

Joel W. Neal, MD, PhD Released: February 16, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Daiichi Sankyo, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue